Specific immune response in the human respiratory tract following oral immunization with live typhoid vaccine

Forrest, B. D.; LaBrooy, Justin T.; Robinson, Prema; Dearlove, C E; Shearman, D. J. C.

doi:10.1007/978-94-009-1848-1_94

Cited by 15 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From Fig. 1 it is evident that oral vaccination with the three alternate-day doses of 1011 S. typhi Ty2la gave rise to a significant increase in postprimary vaccination intestinal anti-typhoid specific IgA response which did not differ significantly between any of the subject groups A to D. This was expected from our previous observations (6)(7)(8)(9). It was clear from examination of the day 42-day 43 (groups A, B, and C) and day 49 (group D) samples in Fig.…”

Section: Resultssupporting

confidence: 73%

Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a

Forrest¹,

LaBrooy²

1992

Vaccine

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 73%

Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a

Forrest¹,

LaBrooy²

1992

Vaccine

View full text Add to dashboard Cite

“…values. (61), IgG present in the saliva was presumed to reach that site as an exudate from serum (22). Possibly due to the poor sensitivity of the sIgA ELISA, we could not demonstrate DSL-specific sIgA responses in saliva of animals dosed with ntPEpilinPAK (data not shown).…”

Section: Vol 73 2005 Novel Intranasal Vaccine For Pseudomonas Infecmentioning

confidence: 84%

“…Although salivary antigen-specific IgG likely results from an exudate from serum (22), antigen-specific salivary sIgA should have reached this location through selective translocation of dimeric IgA across epithelial cells (61). The relative amounts of antigen-specific sIgA observed in serum and saliva levels likely represents antigen-specific precursors of IgA plasma cells that correlate with and precede the appearance of sIgA antibodies in external secretions (12).…”

Section: Discussionmentioning

confidence: 99%

Intranasal Immunization Strategy To Impede Pilin-Mediated Binding ofPseudomonas aeruginosato Airway Epithelial Cells

Hsieh¹,

Tham²,

Feng³

et al. 2005

Infect Immun

View full text Add to dashboard Cite

Prevention of pulmonary Pseudomonas aeruginosa infections represents a critical unmet medical need for cystic fibrosis (CF) patients. We have examined the tenet that a mucosal immunization approach can reduce interactions of a piliated form of this opportunistic pathogen with respiratory epithelial cells. Vaccinations were performed using ntPEpilinPAK, a protein chimera composed of a nontoxic form of P. aeruginosa exotoxin A (ntPE), where the C-terminal loop amino acid sequence of the PAK strain pilin protein was inserted in place of the ntPE Ib domain. Intranasal (i.n.) immunization of BALB/c mice with ntPEpilinPAK generated both serum and saliva immune responses. A series of in vitro studies showed that diluted samples of saliva obtained from immunized mice reduced pilin-dependent P. aeruginosa binding to polarized human tracheal epithelial cells, protected human pulmonary epithelial cells from cytotoxic actions associated with bacterial challenge, and reduced exotoxin A toxicity. Overall, i.n. administration of ntPEpilinPAK induced mucosal and systemic immune responses that may be beneficial for blocking early stage adhesion and/or infection events of epithelial cell-P. aeruginosa interactions at oropharyngeal surfaces.

show abstract

“…The measurement of strain-specific humoral immune responses, including antibody-secreting cells (ASC) and/or serum antibodies, is a fundamental part of assessing the immunogenicity of live oral Salmonella vaccines. Ty21a and other candidate typhoid vaccines (including CVD 909) are capable of eliciting S. Typhi-specific antibodies (e.g., against O and H antigens) (25,29,36,39,41,43,44), as well as cross-reactive antibodies against S. Paratyphi A and S. Paratyphi B (29). Nevertheless, the role of such antibodies, if any, in protection from disease or in the elimination of intracellular bacteria is not well understood.…”

Section: Discussionmentioning

confidence: 99%

Live Oral Salmonella enterica Serovar Typhi Vaccines Ty21a and CVD 909 Induce Opsonophagocytic Functional Antibodies in Humans That Cross-React withS. Paratyphi A andS. Paratyphi B

Wahid

Zafar

McArthur

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

S almonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen, is the causative agent of typhoid fever, the most prevalent form of enteric fever, resulting in an estimated 21.7 million cases and 200,000 deaths per year worldwide (1). However, infection with Salmonella enterica serovar Paratyphi A (paratyphoid A fever) or Salmonella enterica serovar Paratyphi B (paratyphoid B fever) causes similar clinical manifestations (2). While less prevalent than typhoid fever, paratyphoid fever occurs in an estimated 5.4 million cases each year (3-6). Recent reports indicate that paratyphoid A fever is on the rise in areas of endemicity (e.g., South and Southeast Asia, China) and among travelers returning from those areas (3-6). The emergence of multiple antibiotic-resistant Salmonella strains has increased the health risks posed by these enteric fever infections (7).Currently, two licensed vaccines against typhoid fever are available worldwide, parenteral Vi polysaccharide (Vi) and oral live attenuated Ty21a. Nevertheless, each of these vaccines exhibits limitations that have fostered the development of a new generation of vaccines, including both of the engineered live oral typhoid vaccines (e.g., CVD 908-htrA [⌬aroC ⌬aroD ⌬htrA] and CVD 909 [CVD 908-htrA further engineered to constitutively express Vi]) (8) and the M01ZH09 (⌬aroC ⌬ssaV) (9) and Vi carrier protein conjugate vaccines (10). There are, however, no available licensed vaccines against S. Paratyphi A or B.Whole-genome comparative analysis has revealed a high degree of homology among S. Typhi, S. Paratyphi A, and S. Paratyphi B at the DNA level, suggesting the theoretical potential for vaccines against S. Typhi to offer some degree of cross-protection against S. Paratyphi A and S. Paratyphi B (11,12). Vi-based vaccines cannot confer cross-protection, since neither S. Paratyphi A nor S. Paratyphi B expresses Vi antigen. In contrast, large-scale field trials of the efficacy of the oral Ty21a vaccine have documented a moderate level of cross-protection against S. Paratyphi B but not against S. Paratyphi A (13-15). Therefore, the development of an effective vaccine against S. Paratyphi A has emerged as a public health priority (16).We and others have extensively studied the induction of S. Typhi-specific humoral and cellular immune responses (cell-mediated immunity [CMI]) following immunization with Ty21a and other live oral typhoid vaccines in humans (9,(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28) and have also begun to explore the cross-reactive immune responses elicited by the S. Typhi live oral vaccines against S. Paratyphi A and S. Paratyphi B that might explain the observed cross-protection and its serovar limitations (29,30).The capacity of oral typhoid vaccines to induce humoral responses has been well documented, but information on the functional capacity of the induced antibodies has been sparse except for a few reports on specific antibody-enhanced phagocytosis and intracellular killing. In the 1980s, Tagliabue et al. reported that the Ig...

show abstract

Specific immune response in the human respiratory tract following oral immunization with live typhoid vaccine

Cited by 15 publications

References 10 publications

Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a

Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a

Intranasal Immunization Strategy To Impede Pilin-Mediated Binding ofPseudomonas aeruginosato Airway Epithelial Cells

Live Oral Salmonella enterica Serovar Typhi Vaccines Ty21a and CVD 909 Induce Opsonophagocytic Functional Antibodies in Humans That Cross-React withS. Paratyphi A andS. Paratyphi B

Contact Info

Product

Resources

About